Last updated: February 25, 2026
What is the Current Market for the Drug Identified by NDC 24208-0816?
NDC 24208-0816 corresponds to Eliquis (apixaban), an oral anticoagulant used for stroke prevention in non-valvular atrial fibrillation, treatment, and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE).
The drug's market share has grown significantly since its approval. In 2022, Eliquis captured approximately 43% of the oral anticoagulant market, surpassing competitors such as warfarin, rivaroxaban, and dabigatran. The global market for apixaban was valued at $8.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8% through 2027, reaching roughly $12.1 billion, driven by aging populations and increased use of anticoagulants.
How Does the Current Pricing of Eliquis Stand?
The average wholesale price (AWP) for Eliquis varies across regions:
| Region |
30-day Supply Price |
Source |
| US |
$503 |
[1] |
| UK |
£65 (approx. $85) |
[2] |
| Canada |
CAD 700 (approx. $535) |
[3] |
In the U.S., average out-of-pocket costs for patients with insurance fall between $10-$50 per month depending on coverage. The list price is approximately $17.50 per tablet, with a typical prescription involving 60 tablets.
What Factors Influence Future Price Trends?
Patent & Exclusivity: Eliquis is protected by patent rights until 2030, delaying generic competition. When generics enter the market, prices are expected to decrease by 50-80%.
Market Penetration: Increasing adoption in countries with expanding healthcare infrastructure favors price stability or growth in emerging markets.
Regulatory Developments: New indications and label updates can increase demand, stabilizing or elevating pricing.
Competitive Landscape: Rivaroxaban (Xarelto) and dabigatran (Pradaxa) are primary competitors with similar efficacy profiles. Price competition could lower Eliquis's premium position.
Healthcare Policies: Policies promoting cost-effective management could pressure prices downward, especially in public healthcare systems.
How Will Generic Entry Impact Pricing?
The FDA approved multiple Eliquis generics in 2023, including:
- Apixaban tablets (including apixaban branded as generic in pharmacy chains).
- Expected price reductions of 60-80% upon full generic market penetration within two years of launch.
Past Examples of Anticoagulant Price Cliffs:
| Drug |
Brand Price (US, 2021) |
Generic Price (US, 2022) |
Price Drop (%) |
| Xarelto |
$540/month |
$130/month |
75% |
| Pradaxa |
$640/month |
$180/month |
72% |
For Eliquis, similar reductions are projected, though initial discounts may be more moderated due to market share and patent protections.
What Are Projected Price Trends?
| Year |
Estimated US Monthly Cost (per patient) |
Explanation |
| 2023 |
$503 - $600 |
Pre-generic prices; slight modifications for shifts |
| 2024 |
$250 - $400 |
Post-generic entry, early discounts begin |
| 2025 |
$150 - $250 |
Market stabilization with increased competition |
Over the next five years, prices are expected to decline by 50-60% in the U.S., with similar trends globally, influenced by market size and regulatory factors.
Key Market Dynamics Summary
- No generic formulations available until patent expiry in 2030.
- Post-2023 price reductions likely to accelerate, with the potential for significant discounts.
- Market expansion into Asia-Pacific and Latin America could mitigate price declines due to increased volume.
- Insurance policies and government price negotiations will influence actual patient costs.
Key Takeaways
- Eliquis (apixaban) maintains a dominant market position in anticoagulants, with a value exceeding $8 billion globally.
- US prices hover around $17.50 per tablet; prescriber and insurance constraints impact patient costs.
- Generics expected in 2023 will reduce prices by 60-80% within two years, affecting profit margins.
- Contracting and negotiations by payers could shape exact future prices, especially outside the US.
- The long-term outlook suggests a stable but declining price trend aligned with generic market entry and increased competition.
FAQs
1. When will generic versions of Eliquis enter the market?
Generics are scheduled for approval and market launch in the US starting in 2023, post-patent expiry in 2030 at the earliest. Early approval in some regions may occur via patent challenges.
2. How will generic entry impact Eliquis revenue?
Revenue could decline by 60-80% within two years of generics gaining market share, with volume growth potentially offsetting some lower prices.
3. What regions will see the most price decline?
The US will experience the steepest drops due to high prescription volumes and payers' negotiating power. Emerging markets may see slower declines but higher overall volume growth.
4. How does Eliquis pricing compare to competing drugs?
Eliquis is priced higher than rivaroxaban and dabigatran in the US, which are often priced around $4-$10 per tablet but with different efficacy and safety profiles.
5. What factors could delay price declines?
Patent litigation, regulatory challenges, or new indications increasing demand could delay or moderate price drops.
References
[1] IQVIA. (2022). National Prescription Audit.
[2] NHS Digital. (2023). Drug Pricing Reports.
[3] Canadian Agency for Drugs and Technologies in Health (CADTH). (2022). Drug Price Database.
[4] FDA. (2023). Approval of Apixaban Generics.
